Unexplained Hypervitaminemia B12 Natural History Clinical Evolution and Long-Term Outcomes

Background. Elevated total circulating vitamin B12 is a nonspecific biochemical finding that may reflect supplementation, altered cobalamin-binding proteins, liver or kidney disease, malignancy, or analytical interference. “Idiopathic” elevation should describe a finding that remains unexplained after an appropriate assessment, rather than an established disease entity. Methods. This narrative review integrates verified clinical studies, laboratory investigations, and recent systematic reviews, with targeted updates through October 2026. It distinguishes association from causation and evidence on initially unexplained elevation from evidence in established disease. Findings. In a French cohort, solid cancer developed within five years in 20.8% of patients with persistent vitamin B12 elevation, compared with 6.0% with transient elevation and 3.8% with consistently normal values; the adjusted hazard ratio for persistent elevation was 5.90 (95% confidence interval, 2.79–12.45). These estimates arose from a selected clinical population and are not screening probabilities for the general population. A 2025 mortality meta-analysis included 28 studies, 69,610 participants, and 15,815 deaths, but heterogeneity limited universal prognostic interpretation. Recent laboratory studies also support considering immunoglobulin-associated vitamin B12 in selected cases, while the specificity of polyethylene glycol precipitation remains disputed. Elevated total vitamin B12 does not exclude clinically significant deficiency. Conclusions. Evaluation should verify exposure and measurement, identify common organ-specific causes, and pursue malignancy-directed investigations according to clinical findings and persistence. Follow-up intervals and the intensity of surveillance remain unvalidated. Neither treatment directed solely at lowering vitamin B12 nor indiscriminate cancer imaging is supported by the available evidence.